Clinical trials
Metastatic Urothelial Carcinoma clinical trials
Below are recruiting metastatic urothelial carcinoma clinical trials, each written for real people, not researchers. We’re tracking 127 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Phoenix, ArizonaAges 18 years+ - NCT07129993RecruitingPhase 2/Phase 3
Study of datopotamab deruxtecan with chemo for advanced bladder cancer
This trial is testing a new drug combination for advanced bladder cancer that has grown despite previous treatment. It pairs a targeted therapy (datopotamab deruxtecan) with chemotherapy, and the goal is to see if it can slow down or stop the cancer better than standard chemo alone.
Fullerton, CaliforniaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT06862219RecruitingPhase 4
Enfortumab Vedotin safety study for advanced urothelial cancer
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
Patna, BiharAges 18 years+ - NCT07393542RecruitingPhase 3
Combination treatment for advanced bladder cancer
This trial tests a new combination of two medications, SHR-A2102 and adebrelimab, for people with advanced bladder cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07756437Recruiting
Blood test for detecting bladder cancer DNA
This study is testing a simple blood test that looks for cancer DNA in your blood. The goal is to see if it can accurately detect muscle-invasive bladder cancer or upper tract urothelial cancer.
Ghent, East FlandersAges 18 years+ - NCT06196736RecruitingPhase 3
Comparing a new drug to chemo for advanced bladder cancer
This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06079112RecruitingPhase 1/Phase 2
New drug combo for advanced bladder cancer
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT07034053RecruitingPhase 1/Phase 2
Clofarabine for advanced bladder cancer
This trial tests the drug clofarabine in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for those who have already tried standard treatments or chose not to have them.
ViennaAges 18 years+ - NCT07048457RecruitingPhase 2
Surgery for metastatic bladder cancer after initial treatment
This trial tests whether removing the primary bladder tumor and any remaining metastatic spots after initial medication (enfortumab-vedotin) improves outcomes for people with a limited number of metastases (5 or fewer). It is for those whose cancer has responded or stabilized on treatment.
New Haven, ConnecticutAges 18 years+ - NCT07633353Enrolling by invitation
Real-World Outcomes of a New Treatment for Advanced Kidney Cancer
This study looks at how well two newer cancer drugs (enfortumab vedotin and pembrolizumab) work together for advanced upper tract urothelial carcinoma—a rare kidney cancer. Researchers are collecting information from hospitals in France to understand how patients respond and what side effects occur in everyday care.
NîmesAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT06405425RecruitingPhase 2
Study of BL-B01D1 and immunotherapy for advanced bladder cancer
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04623502Recruiting
Study of kidney and bladder cancer metabolism during surgery
This study looks at how kidney and bladder (urothelial) tumors use fuel by taking samples during surgery or biopsy. It may help researchers learn what drives these cancers and guide better future treatments.
Dallas, TexasAges 18 years+ - NCT04678362RecruitingPhase 2
Maintenance treatment with talazoparib plus immunotherapy for bladder cancer
This trial tests whether continuing two medicines after your initial platinum chemotherapy can help keep your urothelial (bladder/urine tract) cancer from coming back or worsening. It is for people whose cancer shrank or stayed stable after chemotherapy and who cannot be cured with surgery or radiation.
AngersAges 18 years+ - NCT04693377Recruiting
Freezing tumor treatment plus targeted radiation for painful bone spread
This study tests whether combining a “freezing” procedure (cryoablation) with focused external radiation (SBRT) can reduce pain from bone metastases. It’s for people with certain cancers that have spread to bone and are having significant pain in a specific bone spot.
Houston, TexasAges 18 years+ - NCT04724018RecruitingPhase 1/Phase 2
Enfortumab and sacituzumab for metastatic bladder cancer
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT04878029RecruitingPhase 1
Cabozantinib plus enfortumab for advanced bladder cancer after immunotherapy
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
Atlanta, GeorgiaAges 18 years+ - NCT05037279RecruitingPhase 3
Testing BCG treatment for bladder cancer after full tumor removal
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
Vancouver, British ColumbiaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05302284RecruitingPhase 3
Testing RC48-ADC plus toripalimab for first-time urothelial cancer
This trial tests whether RC48-ADC combined with toripalimab works better as the first treatment for urothelial cancer that cannot be removed by surgery or has spread. It may help shrink tumors and improve outcomes in people whose cancer has the right HER2 and other eligibility features.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05562830RecruitingPhase 1/Phase 2
Study for bladder or urinary tract cancer after PD-1 failure
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
Orange, CaliforniaAges 18 years+ - NCT05656235RecruitingPhase 2
Study of keeping kidneys longer in upper tract bladder cancer
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+
Hear when a new Metastatic Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Metastatic Urothelial Carcinoma trials by city
Studies with a site in or near these metro areas.
Metastatic Urothelial Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for metastatic urothelial carcinoma?
- Yes. Clin2 currently lists 127 recruiting metastatic urothelial carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic urothelial carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic urothelial carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.